ERBB2 and neoplasm: In addition to providing a potential explanation for HER2 overexpression in non-ERBB2 amplified UC tumors, our findings emphasize the need to look beyond ERBB2 amplification when using a tumor DNA-based assay to help assess HER2 expression status in UC, an important biomarker for novel HER2-targeted ADCs.